E
Elizabeth A. Harvey
Researcher at Harvard University
Publications - 12
Citations - 995
Elizabeth A. Harvey is an academic researcher from Harvard University. The author has contributed to research in topics: Epilepsy & Anticonvulsant. The author has an hindex of 9, co-authored 12 publications receiving 967 citations.
Papers
More filters
Journal ArticleDOI
The teratogenicity of anticonvulsant drugs.
Lewis B. Holmes,Elizabeth A. Harvey,Brent A. Coull,Kelly B. Huntington,Shahram Khoshbin,Ailish M. Hayes,Louise Ryan +6 more
TL;DR: A distinctive pattern of physical abnormalities in infants of mothers with epilepsy is associated with the use of anticonvulsant drugs during pregnancy, rather than with epilepsy itself.
Journal ArticleDOI
The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age.
TL;DR: The results suggest that the teratogenic effects of phenytoin may include an effect on cognitive function, which has been found in studies of animals exposed to pheny toin in utero.
Journal ArticleDOI
The Teratogenicity of Anticonvulsant Drugs
Lewis B. Holmes,Elizabeth A. Harvey,Brent A. Coull,Kelly B. Huntington,Shahram Khoshbin,Ailish M. Hayes,Louise Ryan +6 more
TL;DR: In this article, the authors found that the frequency of major malformations, growth retardation, and hypoplasia of the midface and fingers is increased in infants exposed to anticonvulsant drugs in utero.
Journal ArticleDOI
Intelligence and physical features of children of women with epilepsy.
Lewis B. Holmes,Peter B. Rosenberger,Peter B. Rosenberger,Elizabeth A. Harvey,Shahram Khoshbin,Shahram Khoshbin,Louise Ryan +6 more
TL;DR: Confidence in concluding that there was no difference between seizure history and control infants was strengthened by the fact that no statistically significant differences were observed with respect to multiple outcomes, including eight related measures of intelligence.
Journal ArticleDOI
Anticonvulsant teratogenesis: I. A study design for newborn infants.
TL;DR: There was a significant increase in major malformations, microcephaly or growth retardation among the drug-exposed infants in comparison to both the epilepsy-history and the unexposed infants, and the possible impact of the severity of the mothers' disease on the infants.